{"id":"in10018-in-combination-with-d-1553","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific details on IN10018 and D-1553 individually are limited in public literature, combination immunotherapies typically work by targeting distinct immune checkpoints or pathways to overcome resistance and amplify T-cell activation. This combination approach aims to improve efficacy over single-agent therapy by engaging multiple immune regulatory pathways simultaneously.","oneSentence":"IN10018 in combination with D-1553 represents a dual-targeted immunotherapy approach designed to enhance anti-tumor immune responses through complementary mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:22.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (indication under phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT06166836","phase":"PHASE1, PHASE2","title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-10-12","conditions":"Solid Tumor","enrollment":140},{"nctId":"NCT07174908","phase":"PHASE3","title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2025-09-10","conditions":"Non-Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT05379946","phase":"PHASE1, PHASE2","title":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2022-10-12","conditions":"Solid Tumor","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IN10018 in combination with D-1553","genericName":"IN10018 in combination with D-1553","companyName":"InxMed (Shanghai) Co., Ltd.","companyId":"inxmed-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IN10018 in combination with D-1553 represents a dual-targeted immunotherapy approach designed to enhance anti-tumor immune responses through complementary mechanisms. Used for Advanced or metastatic solid tumors (indication under phase 3 investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}